Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage precision oncology biotechnology company focused on correcting abnormal gene expression by targeting the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to discover and develop therapies against genetically defined dependencies in cancers driven by chromatin dysregulation. Its lead program, FHD-909 (LY4050784), is a selective SMARCA2 inhibitor in Phase 1 development for SMARCA4-mutated cancers, with non-small cell lung cancer as the primary target population. Beyond its lead asset, Foghorn is advancing preclinical programs spanning selective SMARCA2, CBP, EP300, and ARID1B-directed approaches, including enzyme inhibitors and targeted protein degraders. The company also has a strategic collaboration with Eli Lilly covering the selective SMARCA2 program and additional oncology targets.